肺炎球菌结合疫苗临床研究进展  

Progress of clinical research on pneumococcal conjugate vaccine

作　　者：刘琳玉 李英丽 LIU Lin-yu;LI Ying-li(Center for Drug Evaluation,National Medical Products Administration,Beijing 100076,China)

机构地区：[1]国家药品监督管理局药品审评中心,北京100076

出　　处：《中国新药杂志》2024年第15期1544-1550,共7页Chinese Journal of New Drugs

摘　　要：肺炎球菌性疾病对人群健康、社会经济造成了较大的影响,已成为全球值得关注的公共卫生问题之一。目前肺炎球菌性疾病已被WHO列为需“极高度优先”使用疫苗预防的疾病。肺炎球菌疫苗主要包括肺炎球菌多糖疫苗和肺炎球菌结合疫苗。本文将以美国FDA批准的几款肺炎球菌结合疫苗为重点,简要介绍肺炎球菌结合疫苗的临床研究进展,以期为肺炎球菌结合疫苗的临床研发思路提供参考。Pneumococcal disease has caused a significant impact on human health and social economy. It has become one of the public health problems worthy of attention in the world. The WHO classified pneumococcal disease as a “very high priority” for vaccine prevention. Pneumococcal vaccines mainly include pneumococcal polysaccharide vaccine and pneumococcal conjugate vaccine. This article focuses on several FDA-approved pneumococcal conjugate vaccines to briefly introduce the clinical research progress of pneumococcal conjugate vaccines, in order to provide reference for the clinical research and development of pneumococcal conjugate vaccine.

关 键 词：肺炎链球菌 侵袭性肺炎球菌性疾病 肺炎 肺炎球菌结合疫苗 研发策略 

分 类 号：R95[医药卫生—药学]